A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
Key facts
- Who runs it
- University of Wisconsin, Madison
- Where
- Madison, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 49 people enrolled
- Started
- 3 Dec 2012
- Ended
- 24 Dec 2024
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Bevacizumab
- PRDR
- Record updated
- 25 March 2026
- Why it stopped
- slow accrual
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Histologically or molecularly confirmed Grade 3 or 4 glioma, IDH mutant or wildtype, as defined by the 2021 WHO guidelines
- Recurrent disease based on combination of clinical, imaging or histologic confirmation
- Must have previously received radiation and temozolomide to treat their glioma
- Bevacizumab naive patients must be > 5 months post completion of initial radiation therapy
- Bevacizumab exposed patients must be > 3 months post completion of initial radiation therapy
- Age must be >18years, KPS must be greater than 60
- Hematology, chemistry and a urinalysis must meet protocol specified criteria
Who cannot take part
- Uncontrolled hypertension (>160/90mmHg)
- Prior malignancy unless treated >1 year prior to study and have been without treatment and disease free for 1 yr
- active second malignancy unless non-melanoma skin cancer or cervical cancer in situ
- Pregnant or breastfeeding
Where in United States
- University of Wisconsin Hospital and ClinicsMadison, United States
About the trial
What the trial wants to find out
To determine the efficacy of Pulse Reduced Dose Rate (PRDR) radiation when given in 27 fraction over 5.5 weeks with concurrent bevacizumab followed by adjuvant bevacizumab until time of progression in patients with recurrent high grade gliomas (grade III and grade IV). Patients will be placed in 1 of 4 groups based on their histologic diagnosis and prior exposure to bevacizumab.
The 4 groups in the trial
- Bevacizumab-naïve with recurrent IDH wildtype high grade gliomaExisting treatment, for comparison
27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
Treatment: Bevacizumab and PRDR
- Bevacizumab-exposed with refractory recurrent IDH wildtype high grade gliomaExisting treatment, for comparison
27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
Treatment: Bevacizumab and PRDR
- Bevacizumab-naïve with recurrent IDH mutant gliomaExisting treatment, for comparison
27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
Treatment: Bevacizumab and PRDR
- Bevacizumab-exposed with recurrent IDH mutant gliomaExisting treatment, for comparison
27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
Treatment: Bevacizumab and PRDR
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 25 March 2026